Mind Cure Health Targeting Hypoactive Sexual Desire Disorder with MDMA
“Women’s desire issues have not been adequately addressed to date, and we believe this treatment incorporating MDMA and psychotherapy has real promise,” says CEO Kelsey Ramsden
Entries by Emily Jarvie
How Psychedelics Can Help End the Suicide Epidemic
There is increasing scientific evidence that a variety of psychedelics can be used to treat a number of the risk factors linked to suicide, in addition to reducing suicidality.
Psyched Wellness to Study Amanita Muscaria Mushroom Extract for Sleep Disorders
Psychoactive compound muscimol has been shown to treat stress and anxiety, ease muscular pain, and promote restorative sleep.
Psychedelic Business Spotlight: September 17, 2021
This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across the Nordics.
United States’ First Actively Managed Psychedelics ETF Launches on NYSE Arca
PSIL is the third psychedelics ETF to hit the markets after the launch of the world’s first psychedelic ETF earlier this year.
How Mind Medicine Australia Is Tackling Deadly Mental Health Crisis with Psychedelics
Charity co-founder Tania de Jong says Covid-19 pandemic has led to “a huge spike in mental health issues including, very sadly, suicides,” and she believes psychedelics are a solution.
Tim Ferriss and Michael Pollan Team Up to Launch UC Berkeley Psychedelic Journalism Fellowship
Podcaster and author of “The 4-Hour Work Week” will gift the university’s Center for the Science of Psychedelics $800,000 over 3 years to fund fellowship overseen by Professor Pollan.
Detroit Voters Can Decriminalize Psychedelic Plants This November
The proposal asks voters if the city should “decriminalize to the fullest extent permitted under Michigan law the personal possession and therapeutic use of entheogenic plants by adults.”
Hallucinogen Persisting Perception Disorder Is a Psychedelics Problem Ehave Wants to Solve
“HPPD is a discomfort. Some people have it for 10, 15, 20 years and they regret the day they did the drug that caused it,” says the CEO of Ehave.
UW-Madison Study Aims to Increase Minority Representation in Psychedelic Clinical Trials
“Certain demographic groups have been the recipients of more legal scrutiny related to substance use than the majority of the population,” says lead researcher Cody Wenthur.
